Agios Pharmaceuticals (AGIO) Research & Development (2016 - 2025)
Historic Research & Development for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q4 2025 value amounting to $88.1 million.
- Agios Pharmaceuticals' Research & Development rose 633.5% to $88.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $339.5 million, marking a year-over-year increase of 1269.52%. This contributed to the annual value of $339.5 million for FY2025, which is 1269.52% up from last year.
- Agios Pharmaceuticals' Research & Development amounted to $88.1 million in Q4 2025, which was up 633.5% from $86.8 million recorded in Q3 2025.
- In the past 5 years, Agios Pharmaceuticals' Research & Development registered a high of $91.9 million during Q2 2025, and its lowest value of $57.7 million during Q1 2021.
- Its 5-year average for Research & Development is $73.7 million, with a median of $72.6 million in 2024.
- Within the past 5 years, the most significant YoY rise in Agios Pharmaceuticals' Research & Development was 24395.78% (2021), while the steepest drop was 3680.74% (2021).
- Agios Pharmaceuticals' Research & Development (Quarter) stood at $73.3 million in 2021, then decreased by 4.09% to $70.3 million in 2022, then increased by 10.23% to $77.5 million in 2023, then increased by 6.87% to $82.8 million in 2024, then rose by 6.33% to $88.1 million in 2025.
- Its Research & Development stands at $88.1 million for Q4 2025, versus $86.8 million for Q3 2025 and $91.9 million for Q2 2025.